ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches
Go back to ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches| ORION MARINE GROUP, Inc. (NYSE: ORN) | Delayed: 16.41 +0.39 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.02 | 52 Week High | $9.48 | |||
| Open | $15.91 | 52 Week Low | $3.25 | |||
| Day High | $16.46 | P/E | N/A | |||
| Day Low | $15.72 | EPS | $-0.01 | |||
| Volume | 1,879,525 | |||||
